Eton Pharmaceuticals Inc
NASDAQ:ETON

Watchlist Manager
Eton Pharmaceuticals Inc Logo
Eton Pharmaceuticals Inc
NASDAQ:ETON
Watchlist
Price: 12.66 USD 1.28% Market Closed
Market Cap: 327.1m USD
Have any thoughts about
Eton Pharmaceuticals Inc?
Write Note

Eton Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eton Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Eton Pharmaceuticals Inc
NASDAQ:ETON
Interest Income Expense
$713k
CAGR 3-Years
N/A
CAGR 5-Years
12%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Interest Income Expense
$745m
CAGR 3-Years
19%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Interest Income Expense
$859m
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Interest Income Expense
-$984m
CAGR 3-Years
N/A
CAGR 5-Years
-16%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Interest Income Expense
-$426.9m
CAGR 3-Years
-100%
CAGR 5-Years
-12%
CAGR 10-Years
-36%
No Stocks Found

Eton Pharmaceuticals Inc
Glance View

Market Cap
327.1m USD
Industry
Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.

ETON Intrinsic Value
13.52 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Eton Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
713k USD

Based on the financial report for Sep 30, 2024, Eton Pharmaceuticals Inc's Interest Income Expense amounts to 713k USD.

What is Eton Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
12%

Back to Top